22:34:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-08-29 Halvårsrapport
2025-04-10 Årsstämma
2025-03-07 Bokslutskommuniké 2024
2024-08-29 Halvårsrapport
2024-04-29 Årsstämma
2024-04-11 X-dag ordinarie utdelning MONSO 0.00 DKK
2024-03-06 Bokslutskommuniké 2023
2023-09-07 Halvårsrapport
2023-04-13 X-dag ordinarie utdelning MONSO 0.00 DKK
2023-04-12 Årsstämma
2023-03-08 Bokslutskommuniké 2022
2022-12-20 Extra Bolagsstämma 2022
2022-08-31 Halvårsrapport
2022-04-07 X-dag ordinarie utdelning MONSO 0.00 DKK
2022-04-06 Årsstämma
2022-03-09 Bokslutskommuniké 2021
2021-11-16 Extra Bolagsstämma 2021
2021-08-26 Halvårsrapport
2021-04-15 X-dag ordinarie utdelning MONSO 0.00 DKK
2021-04-14 Årsstämma
2021-03-10 Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorInformationsteknik
IndustriProgramvara
Monsenso är verksamt inom IT-sektorn. Bolaget är specialiserat inom tillhandahållandet av digitala uppföljningssystem för vård och omsorg, samt sjukhus. Lösningarna är mjukvarubaserade och används huvudsakligen för uppföljning av patienters hälsotillstånd, samt för intern bevakning och analys. Störst verksamhet återfinns inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-11-01 15:15:55

1.11.2023 15:15:53 CET | Monsenso | Company Announcement

Monsenso signs a new agreement with a leading pharmaceutical company to implement its solution for decentralised patient-centric real-world data collection in a chronic disease area.

Company announcement no. 15-2023

Copenhagen, 2023.11.01

(This message includes inside information)

Under the new agreement, Monsenso will deliver and support real-world patient data collection for a decentralised patient-centric study expected to take place over the next 12 months. 

The agreement and the solution delivered build on Monsenso’s existing platform, which will be customised to support the specific study and the disease of the patient group. It also includes developing new features to support the patient-centric real-world data study, which will position Monsenso’s solution even stronger in the future. 

“With this project, we hope to contribute to getting deeper learnings on which treatments work for which patients by continuously engaging and collecting real-world data from patients.

The potential of this engagement is significant - both with the pharmaceutical company itself across other geographies and disease areas as well as with similar companies.” says Thomas Lethenborg, CEO of Monsenso.

The project comes one year into the start of the PhaseV research project, where Monsenso further develops its solution to fully support decentralised real-world data studies and trials in collaboration with leading pharmaceutical companies and research institutions.

The agreement is not expected to impact Monsenso's revenue projections for 2023, but it is expected to contribute to the growth in the coming years.

Further information: 

Monsenso:

CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com 

Certified Adviser:

Norden CEF A/S
John Norden
Tel. +45 20 72 02 00
E-mail: jn@nordencef.dk

 

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com

Attachments